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Aims: Therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely man-
ner according to evidence-based clinical guidelines, is a key reason for uncontrolled hypergly-
caemia in patients with type 2 diabetes. The aims of this systematic review were to identify
how therapeutic inertia in the management of hyperglycaemia was measured and to assess its
extent over the past decade.
Materials and Methods: Systematic searches for articles published from January 1, 2004 to
August 1, 2016 were conducted in MEDLINE and Embase. Two researchers independently
screened all of the titles and abstracts, and the full texts of publications deemed relevant. Data
were extracted by a single researcher using a standardized data extraction form.
Results: The final selection for the review included 53 articles. Measurements used to assess
therapeutic inertia varied across studies, making comparisons difficult. Data from low- to
middle-income countries were scarce. In most studies, the median time to treatment intensifi-
cation after a glycated haemoglobin (HbA1c) measurement above target was more than 1 year
(range 0.3 to >7.2 years). Therapeutic inertia increased as the number of antidiabetic drugs rose
and decreased with increasing HbA1c levels. Data were mainly available from Western coun-
tries. Diversity of inertia measures precluded meta-analysis.
Conclusions: Therapeutic inertia in the management of hyperglycaemia in patients with type
2 diabetes is a major concern. This is well documented in Western countries, but corresponding
data are urgently needed in low- and middle-income countries, in view of their high prevalence
of type 2 diabetes.
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1 | INTRODUCTION
The importance of glycaemic control in patients with type 2 diabetes
to reduce the risk of microvascular and macrovascular complications
is well established1–5 and widely recognized by current clinical
guidelines.6–10 For example, the joint position statement of the
American Diabetes Association (ADA) and the European Association
for the Study of Diabetes (EASD) advocates a change of therapy if
glycated haemoglobin (HbA1c) targets are not achieved after
3 months.6
Despite the introduction of many glucose-lowering therapies that
have proved to be efficacious in clinical trials, glycaemic control
remains suboptimal in many patients globally. For example, in
European countries with broad access to glucose-lowering therapies,
the GUIDANCE (N = 7597) and PANORAMA (N = 5817) studies
showed that only 53.6% and 62.6% of patients, respectively,
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achieved the recommended HbA1c target of ≤7% (53 mmol/
mol).11,12
Several studies have identified 2 main reasons for suboptimal
glycaemic control in clinical practice: (1) patient non-adherence to
prescribed treatment and (2) clinical or therapeutic inertia, defined as
the failure to initiate or intensify therapy in a timely manner accord-
ing to evidence-based clinical guidelines in individuals who are likely
to benefit from such intensification.13,14 The reasons for clinical or
therapeutic inertia are multiple and complex, and include patient-,
physician- and system-level barriers.15
The primary objective of this systematic review was to identify
studies assessing the extent of therapeutic inertia in the treatment of
hyperglycaemia in different populations of patients with type 2 diabe-
tes. The secondary objective was to provide an overview of how
therapeutic inertia was defined and assessed in different studies.
Assessing the extent of therapeutic inertia is key to implementing
interventions to reduce its occurrence, which will contribute to
improving glycaemic control and ultimately patient outcomes.
2 | MATERIALS AND METHODS
This systematic review was registered with the International Prospec-
tive Register of Systematic Reviews (PROSPERO) on April 13, 2016
(registration number CRD42016036483) and followed Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines.
2.1 | Data sources and searches
Systematic searches for articles published from January 1, 2004 to
August 1, 2016 were conducted in MEDLINE and Embase using the
OvidSP database search interface. A start date of January 1, 2004 was
chosen, to include the seminal article on therapeutic inertia in the
management of patients with type 2 diabetes by Brown et al. pub-
lished in 2004.16 This period also covers the publication of results
from several outcome studies such as the Action in Diabetes and Vas-
cular Disease: Preterax and Diamicron MR Controlled Evaluation
(ADVANCE) study,5 the Action to Control Cardiovascular Risk in Dia-
betes (ACCORD) study,17 and the 10-year follow-up of the UK Pro-
spective Diabetes Study (UKPDS),2 which may have had an impact on
the management of patients with type 2 diabetes in clinical practice.
Medical Subject Headings were used when available. A Medical
Subject Heading for clinical or therapeutic inertia does not exist.
Therefore, related terms were used instead (eg, “clinical competence,”
“health care delivery” and “guideline adherence”). Detailed search
strings used for both MEDLINE and Embase, and the corresponding
numbers of identified publications are shown in Tables S1 and S2,
respectively.
2.2 | Study selection
Broad inclusion criteria were used to minimize the risk of excluding
relevant studies. All publications involving studies of patients with
type 2 diabetes that reported a quantitative measure of therapeutic
inertia were included. Conversely, articles covering studies with insuf-
ficient data (eg, those without a description of the intensification step
and those not reporting the glycaemic level threshold used to deter-
mine whether treatment intensification was required) were excluded.
No language restrictions were imposed, to increase the likelihood of
finding data from as many countries as possible. Congress abstracts
were excluded from this systematic review because they do not pro-
vide sufficient data for effective analysis. Non-original research arti-
cles (eg, editorials, letters, comments, guidelines and reviews) were
also excluded. No other quality criteria were used to exclude studies
from the systematic review.
Two researchers, S. Pi. and Andrew Mayhook (Oxford Pharma-
Genesis, Oxford, UK), screened all titles and abstracts independently,
in accordance with the inclusion and exclusion criteria described
above. Full texts were retrieved for publications that met the inclu-
sion criteria and for those that could not be adequately assessed for
inclusion with the information provided in the abstract. The
2 researchers independently assessed the full texts for inclusion and
discussed their decisions before reaching a consensus on the final list
of articles to be included in the review.
2.3 | Data extraction
Data were extracted by a single researcher (S. Pi.). A standardized form
was used to collect the following items when available: authors, year of
publication, location, study design, period, sample size, patient and phy-
sician characteristics, definition of treatment intensification, glucose-
lowering agents used before and after treatment intensification, and
measure(s) of therapeutic inertia (including the HbA1c threshold used
to identify patients who required treatment intensification).
3 | RESULTS
Out of 7698 combined search results, 53 articles were identified that
reported at least 1 measure of therapeutic inertia in the management
of hyperglycaemia in individuals with type 2 diabetes.16,18–69 The main
reasons for exclusion of publications other than duplicates and those
covering irrelevant topics were that they reported non-original
research (eg, editorials, letters, comments and guidelines) or they were
congress abstracts (Figure 1). In addition, articles reporting the time to
treatment intensification without reporting HbA1c results (eg, the time
from type 2 diagnosis to insulin therapy initiation) were excluded.
3.1 | Study characteristics
Study characteristics are summarized in Table S3. The majority of
studies were conducted in North America (29 studies) and
Europe (20 studies). Three studies were carried out in Asia,35,47,53
and a single study was conducted in Israel.62 Articles mainly
reported data from cohort studies, using data from medical
records or chart reviews,20–22,26,28,30,32,44,46,47,51,52,57,60,62,64 or
from claims, clinical research or administrative databases.
16,18,19,23–25,27,29,35–40,42,43,46,50,54–59,61,65,66,69 Four articles reported
results from cross-sectional studies, and the data were collected
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using provider questionnaires or surveys.41,45,48,49 A single publica-
tion reported results from a randomized clinical trial that evaluated
the impact of physician education on the management of individuals
with type 2 diabetes,53 and another provided results from a post hoc
analysis of a randomized controlled trial.63
Patients were managed by primary care providers in
21 studies,19,21,25,34,37–39,41,44,45,48,50,53,54,59–61,63–65,67 by both primary
care providers and secondary care specialists in 6 studies,23,30,35,47,58,68
and by secondary care specialists alone in 1 study.69 The healthcare
providers responsible for patient care were not described in
25 studies.16,18,20,22,24,26–29,31–33,36,40,42,43,46,49,51,52,55–57,62,66 Treat-
ment characteristics varied across studies. Among articles that
described therapy before treatment intensification, patients were man-
aged exclusively with oral antidiabetic drugs (OADs) in most
cases.16,18,19,23,28–31,35,39,43,47,50,51,54,58,62,65,66 The study by Brown
et al. also included a group of patients managed with non-
pharmacological treatment (ie, diet and exercise exclusively).16 Two
studies included patients managed with OADs or diet and exercise
alone.22,46 The study by Kristensen et al. included only patients mana-
ged with non-pharmacological treatment.40 A single study considered
3 different treatment groups (OADs alone, insulin alone, and diet and
exercise alone),68 and 2 others investigated patients treated with OADs
and/or injectable drugs.25,26 Another group of studies included only
patients who were not treated with insulin but did not describe their
therapies in more detail (ie, glucagon-like peptide-1 [GLP-1] receptor
agonists were not explicitly excluded).24,36,37,41,52,55,60,61,64,69 By
contrast, a study by Khunti et al. assessed treatment intensification
in patients whose therapies included basal insulin.38 Fifteen
publications did not describe the treatments used before
intensification.21,26,27,32,33,42,44,45,48,49,53,57,59,63,67
3.2 | Measures of therapeutic inertia
There is no accepted measure to describe clinical or therapeutic iner-
tia. For the purpose of this systematic review, studies were classified
into 4 categories based on the measurement(s) used to quantify
MEDLINE
Fields: MeSH terms or title/abstract
Date range: January 2004 to July 2016
N = 3085
Screened by title: N = 7695
Screened by abstract: N = 1583
Screened by full text: N = 107
Included in review: N = 53
Embase
Fields: Subject headings or title/abstract
Date range: January 2004 to July 2016
N = 6428
Duplicates: N = 1818
Excluded: N = 6112
Reasons
Irrelevant topic (N = 4345)
Editorial/letter/comment (N = 1072)
Guideline (N = 471)
Congress abstract (N = 102)
Meeting report (N = 57)
Case report (N = 43)
Other (N = 22)
Excluded: N = 1476
Reasons
Irrelevant topic (N = 1179)
Congress abstract (N = 161)
Review (N = 80)
Editorial/letter/comment (N = 44)
Other (N = 12)
Excluded: N = 54
Reason
Insufficient data for analysis (N = 54)FIGURE 1 Flow diagram of study
selection process. Titles, abstracts and full
texts were screened independently by
2 researchers
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clinical/therapeutic inertia: (1) the mean or median length of time
between at least one HbA1c measurement above a certain threshold
and treatment intensification18,23,28,38,43,50,54,56,62,66; (2) the propor-
tion of patients with at least 1 HbA1c measurement above a certain
threshold who received treatment intensification within a given time
frame18,19,21,22,24,25,27–29,31,32,35,37,40,42,43,46,47,50–53,55–66; (3) the gly-
caemic burden, defined as the length of time during which
a patient had an HbA1c level above a certain threshold
during a given period of time16,34,36,39,69; and (4) all other
measurements.20,26,30,33,34,41,44,45,48,49,67,68 HbA1c thresholds and
the lengths of time to assess therapeutic inertia varied widely across
the 53 studies, making comparisons difficult.
3.3 | Time to treatment intensification
Results from the 10 publications that reported the median time to
treatment intensification are shown in Table S3 and Figure 2. For
patients who received a single OAD,23,28,29,50,62,66 the median time to
treatment intensification with any drug (ie, by addition of 1 OAD or
insulin/other injectable drug) was 0.3 to 2.7 years after at least
1 HbA1c measurement above target. The time to treatment intensifi-
cation was generally longer in studies that included patients treated
with more than one OAD and ranged from 1.3 to 4.9 years.18,43,54,56
In most of these studies, less than 50% of the patients received treat-
ment intensification before the end of the follow-up period. The study
by Rubino et al. specifically reported treatment intensification with
insulin in patients using 2 or more OADs.54 The time to treatment
intensification estimated by Kaplan–Meier survival analysis was 4.9
and 4.2 years for patients with HbA1c levels of ≥8.0% and ≥9.0%,
respectively. A single study assessed therapeutic inertia in patients
using basal insulin.38 The time to treatment intensification (addition of
bolus insulin, premix insulin or a GLP-1 receptor agonist) was esti-
mated by Kaplan–Meier survival analysis to be 3.7 and 3.2 years for
patients with HbA1c levels of ≥7.5% and ≥8.0%, respectively. For each
of the 5 studies that considered different HbA1c targets,23,28,38,50,54
the median time to treatment intensification decreased with increasing
HbA1c targets regardless of the index treatment.
First author,
year
Country Study
period
N* Index
treatment
TI (addition to index
treatment)
Patients who
received TI, %†
HbA1c
threshold‡
Fu, 201128 USA 1997–2008 11,525 Metformin OAD or injectable
Conthe, 201123 Spain 2008 1,202 1 OAD OAD or injectable
Paul, 201550 UK 1990–2012 30,471 1 OAD OAD or insulin
Rubino, 200754 UK 2000–2006 2,501 ≥2 OADs Insulin
Khunti, 201638 UK 2004–2013 6,072
Basal
insulin
Bolus or premix insulin
or GLP-1 RA
Schwab, 201656 USA 2008–2009 8,463 Any drug(s)
OAD or injectable
or switch
64 ≥7.0% 1.2
Not reported 7.0–7.9% 1.6
Not reported 8.0–8.9% 0.7
Not reported ≥9.0% 0.4
Dose increase 20 >7.0% 0.3**
Tunceli, 201562 Israel 2009–2011 7,705 Metformin OAD or injectable 34 >7.0% 0.3**
Switch 3 >7.0% 0.4**
Yu, 201666 USA 2009–2011 7,109 Metformin OAD or injectable 38 >7.0% >1.0††
Not reported ≥6.5% 2.7
Not reported ≥7.0% 2.0
71 ≥7.0%§ 1.3
74 ≥7.0%|| 1.4
77 ≥7.5%§ 1.2
78 ≥7.5%|| 1.2
48 ≥7.0% 2.0‡‡
Lin, 201543 USA 2007–2012 79,805 ≥1 OAD OAD or injectable 50 Variable¶ 1.9‡‡
50 Variable# 1.9‡‡
Ajmera, 201518 USA 2007–2012 16,653 2 OADs OAD or insulin 49 ≥8.0% 1.5**
34 ≥8.0% 4.9‡‡
31 ≥9.0% 4.2‡‡
31 ≥7.5% 3.7‡‡
Not reported ≥8.0% 3.2‡‡
Not reported ≥9.0% 1.3
0.0 1.0 2.0 3.0 4.0 5.0 6.0
Median time to TI, years
FIGURE 2 Median time to treatment intensification. Data are given as median times to treatment intensification from the time HbA1c level was
above the threshold shown in the table, unless otherwise stated. *Total number of patients for whom treatment intensification was required in
each study. †Proportion of patients who received treatment intensification by the end of the study period. ‡HbA1c target used to define
inadequate glycaemic control in patients who required treatment intensification. §Consistently above HbA1c target for 1 year post diagnosis.
||Consistently above HbA1c target for 2 years post diagnosis. ¶Modified HbA1c target defined by Ismail-Beigi et al. that was based on patient
age and the presence or absence of macrovascular and microvascular complications, resulting in an individualized HbA1c level between ≤6.5%
and <8.0%.70 #Modified Healthcare Effectiveness Data and Information Set (HEDIS) target of HbA1c <7.0% for patients aged <65 years without
evidence of significant morbidities and HbA1c <8.0% for all other patients (set by the National Committee for Quality Assurance Healthcare in
2013). **Median time to treatment intensification calculated only for patients who received treatment intensification during the study period.
††Fewer than 50% of patients had received treatment intensification by the end of the study period. ‡‡Estimated by Kaplan–Meier analysis.
GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; OAD, oral antidiabetic drug; TI, treatment intensification
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3.4 | Proportion of patients who received treatment
intensification
A total of 34 studies reported the proportions of patients who
received treatment intensification within a given a period of time
(Table S3).18,19,21,22,24,25,27–29,31,32,35,37,40,42,43,46,47,50–53,55–66 Results
from studies that included a single treatment intensification step (eg, a
specific number of OADs at baseline) and those combining several
baseline treatments (eg, baseline treatment described as other than
insulin) are summarized in Figures 3 and 4, respectively.
In most of these studies, less than 50% of patients received
treatment intensification for follow-up periods of less than
12 months. Exceptions were observed for patients managed with diet
and exercise only at baseline40 and for patients with HbA1c levels
≥9.0%.47,53 Four other studies found treatment intensification in
more than 50% of patients within 6 months or less of having an
HbA1c level above target.35,55,57,63 In 3 of these studies, patients
were managed by physicians taking part in a pay-per-performance
programme,35 or they were members of a large, integrated managed
care consortium (Kaiser Permanente Northern California).55,57 The
fourth study was a post hoc analysis of a randomized controlled trial
concerning the implementation of locally adapted guidelines.63
Unsurprisingly, for studies that considered several follow-up peri-
ods, the proportion of patients who received treatment intensifica-
tion rose with increasing lengths of follow-up. Nevertheless, even
after periods longer than 12 months following an HbA1c measure-
ment above target, the proportion of patients who had received
treatment intensification was only 37% to 79%.18,19,28,51,65 In 4 stud-
ies in which different HbA1c thresholds were analysed, the
3.0 58
6.0 66
3.0 23
6.0 32
12.0 42
24.0 54
3.0 21
9.0 34
15.0 42
24.0 45
12.0 56
12.0 34
12.0 20
12.0 3
12.0 40
60.0 79
12.0 36
14.0 37
12.0 33
4.0 24
6.0 28
12.0 37
24.0 45
14.0 42
14.0 39
0 20 40 60 80 100
Proportion of patients who received TI, %
Period,
months‡
Kristensen, 200840
Rajpathak, 201451
Tunceli, 201562
Watson, 201665
Paul, 201550
Ajmera, 201518
Yu, 201666
Balkau, 201219
Grant, 200731
Balkau, 201219
Balkau, 201219
First author,
year
Fu, 201128
Denmark
USA
Israel
UK
UK
USA
USA
France
USA
France
France
Country
USA
2000–2004
2004–2009
2009–2011
2000–2013
1990–2012
2007–2012
2009–2011
2008–2009
1992–2001
2008–2009
2008–2009
Study
period
1997–2008
315
5,870
7,705
6,710
30,471
16,653
7,109
3,118
2,065
3,118
3,118
N*
12,566
No treatment
Metformin
Metformin
Metformin
1 OAD
2 OADs
Metformin
1 OAD
1 OAD
2 OADs
3 OADs
Index
treatment
Metformin
1 drug
1 OAD
1 OAD or injectable
1 OAD or insulin
1 OAD or insulin
1 drug or dose increase or switch
1 drug
Dose increase
Switch
1 OAD or injectable
1 drug or dose increase
1 drug or dose increase
1 drug or dose increase
1 drug or dose increase
TI (addition to index
treatment)
1 OAD or injectable
6.0 27
6.0 28
6.0 29
6.0 32
12.0 40
12.0 40
12.0 46
12.0 46
24.0 65
24.0 64
24.0 72
24.0 70
>8.0%
>7.5%
>7.0%
>7.0%
>6.5%
>7.0%
>7.0%
>8.0%
HbA1c
threshold†
≥7.0%
≥7.0%
≥7.0%§
≥7.0%||
≥7.5%§
≥7.5%||
≥7.0%§
≥7.0%||
≥7.5%§
≥7.5%||
≥7.0%§
≥7.0%||
≥7.5%§
≥7.5%||
≥8.0%
FIGURE 3 Proportion of patients who received treatment intensification after a given period of time (patients managed with a defined number
of OADs). *Total number of patients for whom treatment intensification was required. †HbA1c target used to define suboptimal glycaemic
control in patients who required treatment intensification. ‡Length of time to assess treatment intensification after HbA1c level was above
target. §Consistently above HbA1c target for 1 year post diagnosis. ||Consistently above HbA1c target for 2 years post diagnosis. HbA1c,
glycated haemoglobin; OAD, oral antidiabetic drug; TI, treatment intensification
KHUNTI ET AL. 431
Lin, 201543 USA 2007–2012 79,805 ≥1 OAD
≥7.0%
Variable||
Variable¶
Shah, 200558 Canada 1999–2000 2,502 ≥1 OAD 1 OAD or insulin or dose increase
Fu, 201629 USA 2009–2013 12,566 ≥1 OAD 1 OAD or injectable ≥8.0%
Davis, 201424 USA 2009 5,721 Not insulin 1 OAD or insulin or dose increase
Reed, 201252 USA 2004–2009 NA Not insulin
1 drug or insulin or dose increase
or switch
Sidorenkov, 201360 Netherlands 2007 3,620 Not insulin 1 drug or dose increase or switch
Sidorenkov, 201361 Netherlands 2007–2009 2,455 Not insulin 1 drug or dose increase
Frayne, 201427 USA 2003–2004 52,526 Not described 1 OAD or insulin or dose increase
Selby, 200957 USA 2000–2004 NA Not described 1 drug or dose increase or switch
Reutens, 201253
Asia
Pacific
2007–2009 308 Not described 1 OAD or insulin or dose increase
Sidorenkov, 201159 Netherlands 2007–2009 1,975 Not described 1 drug or dose increase
van Bruggen, 200963 Netherlands NA 161 Not described 1 drug or dose increase or switch
Bullock, 201322 USA 2008–2009 277 None or ≥1 OAD 1 OAD or insulin or dose increase >10.0% 0.5 35
Huang, 201535 Taiwan 2006–2008 168,876 ≥1 OAD 1 OAD or insulin or dose increase >7.0% 4.0 62
OAD or insulin or GLP-1 RA 6.0 27
OAD 6.0 20
Insulin 6.0 5
GLP-1 RA 6.0 2
OAD or insulin or GLP-1 RA 6.0 30
OAD 6.0 21
Insulin 6.0 6
GLP-1 RA 6.0 3
OAD or insulin or GLP-1 RA 6.0 29
OAD 6.0 21
Insulin 6.0 6
GLP-1 RA 6.0 3
McEwen, 200946 USA 2000–2003 1,093 None or ≥1 OAD 1 OAD or insulin >7.2% 18.0 48
>8.0%# 4.0 37
>8.0%** 4.0 45
6.0 37
12.0 48
Balkau, 201219 France 2008–2009 3,118 1–3 OADs 1 drug or dose increase Variable†† 14.0 39
Osataphan, 201647 Thailand 2010–2014 98 ≥2 OADs Insulin ≥9.0% 3.0 68
Katon, 200937 USA 2001–2007 1,251 Not insulin 1 drug or dose increase or switch ≥8.0% 3.0 40
>7.0% 1.0 17
7.1–7.9% 1.0 12
8.0–8.9% 1.0 20
≥9.0% 1.0 28
7.0–8.9%‡‡ 2.0 5
≥9.0%‡‡ 2.0 24
7.0–8.9%†† 2.0 5
≥9.0%§§ 2.0 26
Schmittdiel, 200855 USA 2005–2006 49,694 Not insulin 1 drug or dose increase or switch ≥7.0% 3.0 60
>7.0% 6.0 35
>8.5% 6.0 36
>7.0%||| 4.0 31
>7.0%¶¶ 4.0 30
>8.5%||| 4.0 31
>8.5%¶¶ 4.0 30
Voorham, 201264 Netherlands 2007 3,589 Not insulin 1 drug or dose increase ≥7.0% 4.0 36
de Vries, 201425 Netherlands 2007–2011 17,091 OAD(s) and/or injectable(s) 1 drug or dose increase or switch ≥7.0% 4.0 48
Schwab, 201656 USA 2008–2009 8,463 OAD(s) and/or injectable(s) 1 drug or switch ≥9.0% 3.0 35
Bolen, 200921 USA 1999–-2001 574† OAD(s) 1 OAD or dose increase ≥8.0% 1.0 22
≥8.0% 0.5 38
≥8.0% 1.0 45
Grant, 200432 USA 1997–1999 2,065 Not described 1 drug or dose increase or switch >8.0% 12.0 52
Lian, 201442 USA 2009–2011 95,300 Not described 1 drug or switch ≥7.0% 1.5 26
≥8.0%## 3.0 56
≥8.0%*** 3.0 57
6.5–6.9%††† 6.0 19
7.0–8.9%††† 6.0 34
≥9.0%††† 6.0 44
6.5–6.9%‡‡‡ 6.0 26
7.0–8.9%‡‡‡ 6.0 42
≥9.0%‡‡‡ 6.0 52
1.0 21
>7.0% 3.0 35
6.0 38
>8.0%‡‡‡ 6.0 57
>8.5%††† 6.0 54
0 20 40 60 80 100
First author,
year
Country
or region
Study
period
N* Index
treatment
TI (addition to index
treatment)
HbA1c
threshold‡
Period,
months§
Proportion of patients who received TI, %
FIGURE 4 Proportion of patients who received treatment intensification after a given period of time (number of drugs before treatment
intensification not clearly defined). *Total number of patients for whom treatment intensification was required. †Total number of clinical encounters
that required treatment intensification. ‡HbA1c target used to define suboptimal glycaemic control in patients who required treatment intensification.
§Length of time to assess treatment intensification after HbA1c level was above target. ||Modified HbA1c target defined by Ismail-Beigi et al., which
was based on patient age and the presence or absence of macrovascular and microvascular complications, resulting in individualized HbA1c levels
between ≤6.5% and <8.0%.70 ¶Modified Healthcare Effectiveness Data and Information Set (HEDIS) target of <7.0% for patients aged <65 years
without evidence of significant morbidities and <8.0% for all other patients (set by the National Committee for Quality Assurance Healthcare in 2013).
#Primary care. **Specialist care. ††HbA1c level >6.5% for 1 OAD, >7.0% for 2 OADs and >8.0% for 3 OADs. ‡‡Before implementation of electronic
health record system. §§After implementation of electronic health record system. ||||One HbA1c measurement above target. ¶¶Two consecutive HbA1c
measurements above target. ##In 2011. ***In 2013. †††Control group. ‡‡‡Intervention group (healthcare professional training on clinical guidelines).
Abbreviations: GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; NA, not available (not reported); OAD, oral
antidiabetic drug; TI, treatment intensification
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proportion of patients who received treatment intensification rose
with increasing HbA1c values.24,50,52,53 By contrast, in 2 studies by
Sidorenkov et al.60,61 the proportions of patients who received treat-
ment intensification were similar for those with HbA1c >7.0% and
those with HbA1c >8.5%.
In the single study that reported proportions of patients receiving
treatment intensification within 6 months for different treatment
regimens,43 proportions were lower for insulin (5% to 6%) and GLP-1
receptor agonists (2% to 3%) than for addition of an OAD (20%
to 21%).
3.5 | Glycaemic burden
Five publications reported glycaemic burden (ie, the length of time
with HbA1c above target during a given period).16,34,36,39,69 Results
of these studies are summarized in Figure 5 and Table S3. The studies
by Brown et al. and Khunti et al. identified patients who required
treatment intensification, and they assessed the glycaemic burden
until treatment intensification.16,39 By contrast, 2 other studies iden-
tified a cohort of patients who initiated insulin and assessed glycae-
mic burden retrospectively.36,69 In the study by Halimi et al.34
patients with poor glycaemic control were identified during a routine
visit, and the length of time their HbA1c level had been above target
was calculated using medical records.
In the study by Brown et al.16 the mean glycaemic burden ranged
from 0.7 to 4.9 years, depending on therapy and HbA1c threshold. Gly-
caemic burden increased with the rising number of OADs used and
was lower for patients with HbA1c levels >8.0% than for those with
HbA1c levels >7.0%. The proportion of patients with HbA1c levels
>8.0% who received treatment intensification by the end of the study
decreased with the increasing number of OADs (19% to 67%). The
study by Khunti et al. reported a median time to treatment intensifica-
tion from 1.1 years to more than 7.2 years,39 the median glycaemic
burden rising with the increasing number of OADs and decreasing with
increasing HbA1c values. The proportions of patients who received
treatment intensification by the end of the study period were similar
for patients with HbA1c levels ≥7.0%, 7.5% and 8.0%, and decreased
with the increasing number of OADs; these proportions were lower
when treatment was intensified with insulin (7% to 22%) than when it
was intensified with an OAD (30% to 67%). Halimi et al. identified
patients who received OADs and whose HbA1c was inadequately con-
trolled (2 consecutive HbA1c measurements ≥6.5%, ≥7.0% and ≥8.0%
for patients treated with 1, 2 and 3 OADs, respectively).34 Although
the HbA1c level had been over target for 0.9 to 1.2 years in these
patients, few individuals (0% to 7%) received treatment intensification
during the inclusion visit. In the study by Zografou et al.69 glycaemic
burden was assessed from diagnosis to insulin treatment initiation; the
median time above target was 0.8 to 4.2 years and decreased with
increasing HbA1c values. In the study by Hugie et al.,36 glycaemic bur-
den (HbA1c >8.0%) before insulin treatment initiation was 0.4 to
1.3 years and rose with the increasing number of OADs.
3.6 | Other measures of therapeutic inertia
In addition to the studies above, 12 others determined the propor-
tions of patients who received treatment intensification without
specifying a time frame30,33,34,44 or measured therapeutic inertia by
assessing the proportion of clinical encounters for which treatment
intensification was recommended by guidelines and did not occur
(Table S3).20,26,41,45,48,49,67,68 In 4 of these studies, treatment intensi-
fication was assessed by questionnaires completed by physi-
cians41,45,49 or patients.48 The different and insufficiently described
methodologies precluded any comparisons among these studies. In
the study by Ziemer et al.,68 treatment intensification rates increased
with rising plasma glucose levels and were higher in specialist care
than in primary care settings. Similarly, in the studies by Parchman
et al.48 and Parnes et al.,49 rates of treatment intensification
increased with rising HbA1c values. An opposite trend was observed
in the study by Lang et al.,41 in which the proportions of patients
who received treatment intensification decreased with increasing
HbA1c values.
4 | DISCUSSION
To our knowledge, this is the first systematic review to analyse the
global extent of therapeutic inertia in the management of hyperglycae-
mia in patients with type 2 diabetes within our search timeframe. The
results clearly demonstrate that delays in treatment intensification are
widespread in both primary and specialist care, and occur at all stages
of the treatment pathway, from initiation of oral therapy after failure
of non-pharmacological treatment (diet and exercise), through addition
of OAD(s), to initiation and intensification of insulin therapy. In studies
that considered several treatments, delay in intensification was found
to increase with rising numbers of OADs. The longest delays were
reported for initiation of insulin, which reflects reticence on the part of
both patients and healthcare professionals to initiate and intensify
insulin therapy, for reasons that include fear of injection pain, potential
side effects (hypoglycaemia and weight gain) and reduced quality of
life, alongside concerns about adherence to treatment.71–74
Although the ADA/EASD joint position statement recommends a
change of therapy if HbA1c targets are not achieved after 3 months,6
the reported times to treatment intensification were generally much
higher than 3 months, and the proportion of patients who received
treatment intensification after this period was low. In all studies that
compared several HbA1c thresholds, higher HbA1c values were asso-
ciated with shorter times to treatment intensification and/or a higher
proportion of patients who underwent treatment change within a
given follow-up period. Although the heterogeneity of the included
studies precluded identification of secular trends in the evolution of
therapeutic inertia, the results suggest that therapeutic inertia has
been a persistent issue over the past decade. As mentioned previ-
ously, inertia does not have an associated Medical Subject Heading
and may have diverse definitions, making the design of the search
string difficult. Although we used a comprehensive search strategy
and identified a large number of studies, some relevant publications
may have been missed. The diversity of inertia measures, patient
populations, treatments and HbA1c targets used to assess glycaemic
control made comparisons among studies difficult and precluded any
meta-analysis of the results. Indeed, the extent of therapeutic inertia
depends on the definitions of treatment goals (based on different
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clinical guidelines), therapies and time windows selected to assess
treatment intensification in individual studies. Despite these limita-
tions, some useful inferences can be drawn from the data.
First, our systematic review highlighted a lack of data on treat-
ment intensification outside North America and Western Europe.
Although searches were not restricted to specific countries or regions
and languages, only 3 studies were conducted in Asia, only 1 in East-
ern Europe (Croatia) and only 1 in Israel. Given the high prevalence
of type 2 diabetes in many low- and medium-income countries,75
studies to quantify and address therapeutic inertia in those countries
may be a valuable opportunity to improve glycaemic control and
patient outcomes.
Brown, 200416 USA 1994–2002 7,208 Change of therapy
Not reported
Halimi, 201234 France 2010 702 1 drug or dose increase
Khunti, 201339 UK 2004–2011 62,896
1 OAD
OAD
Insulin
OAD or insulin
2 OADs
OAD
Insulin
14 ≥7.0%
OAD or insulin
3 OADs Insulin
Zografou, 201469 UK 2002–2011 509 Not insulin Initiation of insulin
Hugie, 201636 USA 2009–2013 90,497 Initiation of insulin 100¶
Diet and exercise >7.0% 1.9
Metformin >7.0% 3.5
Sulfonylurea >7.0% 2.8
Metformin + sulfonylurea >7.0% 4.9
Diet and exercise 67 >8.0% 0.7
Metformin 35 >8.0% 1.6
Sulfonylurea 45 >8.0% 1.4
Metformin + sulfonylurea 19 >8.0% 2.5
≥1 OAD 7§ Variable|| 1.2
1 OAD 7§ ≥6.5% 1.2
2 OADs 7§ ≥7.0% 1.2
≥3 OADs 0§ ≥8.0% 0.9
65 ≥7.0% 2.9#
67 ≥7.5% 1.9#
67 ≥8.0% 1.6#
7 ≥7.0% >7.2#,**
8 ≥7.5% >7.1#,**
9 ≥8.0% >6.9#,**
72 ≥7.0% 2.2#
75 ≥7.5% 1.5#
76 ≥8.0% 1.1#
32 ≥7.0% >7.2#,**
32 ≥7.5% >7.2#,**
30 ≥8.0% >6.9
>7.2#,**
17 ≥7.5% >7.2#,**
20 ≥8.0% >6.9#,**
45 ≥7.0% >7.2#,**
49 ≥7.5% >7.2#,**
50 ≥8.0% 6.3#
18 ≥7.0% >7.1#,**
21 ≥7.5% >6.1#,**
22 ≥8.0% >6.0#,**
>7.0% 4.1#,††
100¶ >8.0% 2.1#,††
>9.0% 0.8#,††
1 OAD >8.0% 0.4
2 OADs >8.0% 0.9
3 OADs >8.0% 1.2
>3 OADs >8.0% 1.3
0.0 2.0 4.0 6.0 8.0
Mean glycaemic burden, years
First author,
year
Country Study
period
N* Index
treatment
TI (addition to index
treatment)
HbA1c
threshold‡
Patients who
received TI, %†
FIGURE 5 Glycaemic burden (defined as the length of time with HbA1c level above target during a given period of time). Data are shown as
means unless otherwise stated. *Total number of patients for whom treatment intensification was required. †Proportion of patients who
received treatment intensification by the end of the study period. ‡HbA1c target used to define glycaemic burden. §Proportion of patients who
received treatment intensification at the inclusion visit. ||HbA1c ≥6.5% for 1 OAD, HbA1c ≥7.0% for 2 OADs and HbA1c ≥8.0% for 3 OADs.
¶Only patients in whom insulin treatment was initiated were included in the study. #Median glycaemic burden. **Fewer than 50% of patients
had received treatment intensification by the end of the study period. ††Glycaemic burden was calculated from type 2 diabetes diagnosis to
initiation of insulin therapy. HbA1c, glycated haemoglobin; OAD, oral antidiabetic drug; TI, treatment intensification
434 KHUNTI ET AL.
Whether the delays in treatment intensification identified in this
review represent true therapeutic inertia may be contentious. Most
of the reviewed studies used generic targets (eg HbA1c level >7.0%
for all patients as opposed to individualized targets) to assess glycae-
mic control and thus therapeutic inertia. Some studies may, therefore,
overestimate the prevalence of therapeutic inertia because treatment
intensification may not be warranted in certain patients (eg, in elderly
individuals). It should be noted, however, that the study by Lin
et al. found similar results for a generic HbA1c target of 7.0% and
2 alternative individualized HbA1c thresholds.43
Other methodological aspects of some of the studies should be
carefully considered when interpreting the results and the degree to
which they represent therapeutic inertia. Several studies quantified
therapeutic inertia by calculating the number of visits during which
treatment intensification was indicated by guidelines but did not
occur.41,45,68 This approach may not provide a representative picture
of therapeutic inertia. At the level of a visit, competing demands may
prevent treatment intensification, particularly in primary care. As vis-
its are time-constrained, physicians and patients may prioritize more
pressing issues (eg, symptomatic comorbidity or counselling for
smoking-cessation) and thus delay treatment intensification to
another visit.48 Competing demands were one of the main reasons
for inaction cited by healthcare providers in the study by Parnes
et al.49 In this context, there is an opportunity for pharmacists to play
an important role in timely treatment intensification. However, none
of the articles included in this review reported data on the manage-
ment of patients by pharmacists. Some studies may also overestimate
the prevalence of therapeutic inertia because they assess treatment
intensification after a single HbA1c measurement above target. Some
physicians may wait for confirmation of suboptimal glycaemic control
(ie, a second consecutive HbA1c measurement above target) before
intensifying treatment, particularly for patients who are close to their
glycaemic target. In that case, assessing treatment intensification
after 2 consecutive measurements above target or using glycaemic
burden is likely to provide a more accurate estimate of true therapeu-
tic inertia. Nevertheless, a study by Sidorenkov et al. found very simi-
lar proportions of patients receiving treatment intensification after a
single HbA1c measurement or after 2 consecutive HbA1c measure-
ments above target.60 These variations in methodology across the
included studies highlight the need for accepted definitions of thera-
peutic inertia for use in clinical research, to ensure that therapeutic
inertia is accurately measured and reported.
Although delay in treatment intensification may be justified for
some patients, it took longer than recommended by current clinical
guidelines for significant proportions of patients to receive treatment
intensification. Therapeutic inertia remains a significant barrier to
adequate glycaemic control in North America and Europe. In other
regions, data are scarce or non-existent, and studies are warranted to
analyse the extent of therapeutic inertia, its causes, and its impact on
glycaemic control and patient outcomes globally. Given the risk of
microvascular and microvascular complications associated with poor
glycaemic control,4,76–79 actions such as healthcare quality-
improvement programmes are urgently required to increase adher-
ence to guidelines and to identify patients who may benefit from
closer glucose monitoring.
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